Dr. Yasmin Thanavala on targeted therapy for liver cancer
2 意见
• 06/28/23
0
0
嵌入
Yasmin Thanavala, PhD, of the Department of Immunology and the Tumor Immunology and Immunotherapy program at Roswell Park Cancer Institute, discusses new research that may help identify those patients with advanced liver cancer who will benefit most from the targeted therapy sorafenib. Read more: http://goo.gl/W0jPX2
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论